ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Organogenesis Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.02+0.02 (+2.03%)
Close on Oct 19, 2026
- Market cap
- $131.25M
- P/E (TTM)
- –
- Dividend yield
- –
Organogenesis Holdings Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Product Revenue | $563.03M | $482.04M | $433.14M | – | – | – | – | – | – | – | 99.8% | +16.8% |
| Grant [Member] | $1.14M | $0 | $0 | – | – | – | – | – | – | – | 0.2% | – |
| Advanced Wound Care | – | $453.64M | $405.51M | $422.23M | $430.24M | $294.62M | $220.74M | $164.33M | $178.90M | $138.73M | – | – |
| Surgical & Sports Medicine | – | $28.40M | $27.63M | $28.66M | $37.12M | $43.67M | $40.24M | $29.12M | $19.61M | – | – | – |
| PuraPly | – | – | – | – | – | – | $126.81M | $69.77M | $109.09M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Organogenesis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.